GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M4 receptor agonist which is under development for the treatment of schizophrenia. It is taken orally. The drug is under development by Novartis. As of March 2026, it is in phase 2 clinical trials for schizophrenia. The drug also is or was under development for another unspecified indication, but no recent development for this use has been reported. Two phase 2 trials for schizophrenia are underway and expected to be completed in April 2027.
See also List of investigational antipsychotics
References


